Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression

Leukemia Research

Volumn 28, Issue 8, 2004, Pages 791-803

  Raza, Azra ^a   Buonamici, Silvia ^b   Lisak, Laurie ^a   Tahir, Sarah ^a   Li, Donglan ^a   Imran, Mehnaz ^a   Chaudary, Nusrat Ijaz ^a   Pervaiz, Hassan ^a   Gallegos, J Alejandro ^a   Alvi, M Imran ^a   Mumtaz, Muhammad ^a   Gezer, Sefer ^a   Venugopal, Parameswaran ^a   Reddy, Poluru ^a   Galili, Naomi ^a   Candoni, Anna ^a   Singer, Jack ^c   Nucifora, Giuseppina ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c Cell Therapeutics Inc   (United States)

Author keywords

Agiogenesis; Aoptosis; Asenic trioxide; EVI1; Melodysplastic syndromes; Talidomide

Indexed keywords

ARSENIC TRIOXIDE; THALIDOMIDE;

ADULT; AGED; AMNESIA; ANOREXIA; ARTICLE; BLEEDING; CATHETER INFECTION; CELLULITIS; CHILL; CHOLECYSTITIS; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DIZZINESS; DRUG RESPONSE; DRUG SENSITIVITY; DYSPNEA; ECG ABNORMALITY; FATIGUE; FEMALE; FEVER; FLUID RETENTION; GENE EXPRESSION; HEADACHE; HEARING LOSS; HIGH RISK PATIENT; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; IN VITRO STUDY; INTESTINE PERFORATION; LARYNX CANCER; LUNG EMBOLISM; MALE; MUSCLE CRAMP; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROPATHY; NEUTROPENIA; NUCLEOTIDE SEQUENCE; PAIN; PANCREATITIS; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SPLEEN SIZE; SWEATING; SYNCOPE; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY FREQUENCY; VISUAL IMPAIRMENT; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC AGENTS; ARSENICALS; CELL LINEAGE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OXIDES; PROTO-ONCOGENES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SPLEEN; THALIDOMIDE; TRANSCRIPTION FACTORS; ZINC FINGERS;

EID: 2942557117     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.11.018     Document Type: Article

References (41)

1. Steensma D.P., Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 27(February(2)): 2003;95-120
2. Paquette R.L. Diagnosis and management of aplastic anemia and myelodysplastic syndrome. Oncology (Huntingt). 16(September(9 Suppl 10)):2002;153-161
3. Sanz G.F., Sanz M.A., Greenberg P.L. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica. 83(April(4)):1998;358-368
4. Deeg H.J., Appelbaum F.R. Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Leuk Res. 24(August(8)):2000;653-663
5. Kasper C., Zahner J., Sayer H.G. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. J Cancer Res Clin Oncol. 128(September(9)):2002;497-502
6. Raza A., Gezer S., Mundle S., Gao X.Z., Alvi S., Borok R., et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 86(1):1995;268-276
7. Bellamy W.T., Richter L., Sirjani D., Roxas C., Glinsmann-Gibson B., Frutiger Y., et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 97(March(5)): 2001;1427-1434
8. Raza A., Meyer P., Dutt D., Zorat F., Lisak L., Nascimben F., et al. Thalidomide produces transfusion independence in long standing refractory anemias of patients with myelodysplastic syndromes. Blood. 98(4):2001;958-965
9. Miller W.H. Jr., Schipper H.M., Lee J.S., Singer J., Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 62(July(14)):2002;3893-3903
10. Morishita K., Parker D.S., Mucenski M.L., Jenkins N.A., Copeland N.G., Ihle J.N. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell. 54(September(6)):1988;831- 840
11. Fears S., Mathieu C., Zeleznik-Le N., Huang S., Rowley J.D., Nucifora G. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci USA. 93(February(4)):1996;1642-1647
12. Sood R., Talwar-Trikha A., Chakrabarti S.R., Nucifora G. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1. Leukemia. 13(March(3)):1999;348-357
13. Chakraborty S., Senyuk V., Sitailo S., Chi Y., Nucifora G. Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles. J Biol Chem. 276(November(48)): 2001;44936-44943
14. Cuenco G.M., Nucifora G., Ren R. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. Proc Natl Acad Sci USA. 97(February(4)):2000;1760-1765
15. Nucifora G. The EVI1 gene in myeloid leukemia. Leukemia. 11(December(12)):1997;2022-2031
16. Soderholm J., Kobayashi H., Mathieu C., Rowley J.D., Nucifora G. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator. Leukemia. 11(March(3)):1997;352-358
17. Pintado T., Ferro M.T., San Roman C., Mayayo M., Larana J.G. Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer. 55(February(3)):1985;535-541
18. Jenkins R.B., Tefferi A., Solberg L.A. Jr., Dewald G.W. Acute leukemia with abnormal thrombopoiesis and inversions of chromosome 3. Cancer Genet Cytogenet. 39(June(2)):1989;167-179
19. Jotterand Bellomo M., Parlier V., Muhlematter D., Grob J.P., Beris P. Three new cases of chromosome 3 rearrangement in bands q21 and q26 with abnormal thrombopoiesis bring further evidence to the existence of a 3q21q26 syndrome. Cancer Genet Cytogenet. 59(April(2)):1992;138-160
20. Fonatsch C., Gudat H., Lengfelder E., Wandt H., Silling-Engelhardt G., Ludwig W.D., et al. Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26). Leukemia. 8(August(8)):1994;1318-1326
21. Secker-Walker L.M., Mehta A., Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol. 91(October(2)):1995;490-501
22. Horsman D.E., Gascoyne R.D., Barnett M.J. Acute leukemia with structural rearrangements of chromosome 3. Leuk Lymph. 16(February(5-6)):1995;369-377
23. Breccia M., Petti M.C., Ottaviani E., Mancini M., D'Elia G.M., Mecarocci S., et al. Diabetes insipidus as first manifestation of acute myeloid leukaemia with EVI1-positive, 3q21q26 syndrome and T cell-line antigen expression: what is the EVI1 gene role? Br J Haematol. 118(August(2)):2002;438-441
24. Sancho J.M., Ribera J.M., Granada I., Navarro J.T., Milla F., Feliu E. Myelofibrosis in myeloid malignancies with 3q26 cytogenetic abnormalities. Haematologica. 85(May(5)):2000;554-555
25. van Doorn-Khosrovani S.B., Erpelinck C., van Putten W.L.J., Valk P.J.M. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood. 101:2003;837-845
26. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. World Health Organization(WHO) International Working Group Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 96(December(12)):2000;3671-3674
27. Sitailo S., Sood R., Barton K., Nucifora G. Forced expression of the leukemia-associated gene EVI in ES cells: a model for myeloid leukemia with 3q26 rearrangements. Leukemia. 13:1999;1639-1645
28. Senyuk V., Chakraborty S., Mikhail F., Zhao R., Chi Y., Nucifora G. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells. Oncogene. 21:2002;3232-3240
29. List A.F. Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia. Semin Oncol. 26(April(2 Suppl 7)):1999;61-65
30. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group. J. Clin. Oncol. 20(May(10)):2002;2429-2440
31. Beran M., Kantarjian H.M. Topotecan (hycamptin) and topotecan-containing regimens in the treatment of hematologic malignancies. Ann NY Acad Sci. 922:2000;247-259
32. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 347(August(7)):2002;481-487
33. Hayashi T., Hideshima T., Akiyama M., Richardson P., Schlossman R.L., Chauhan D., et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther. 1(August(10)): 2002;851-860
34. Zhu J., Chen Z., Lallemand-Breitenbach V., de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2(September(9)): 2002;705-713
35. Chen Z., Chen G.Q., Shen Z.X., Sun G.L., Tong J.H., Wang Z.Y., et al. Expanding the use of arsenic trioxide: leukemias and beyond. Semin Hematol. 39(April(2 Suppl 1)):2002;22-26
36. Davison K., Mann K.K., Miller W.H. Jr. Arsenic trioxide: mechanisms of action. Semin. Hematol. 39(April(2 Suppl 1)):2002;3-7
37. Roboz G.J., Dias S., Lam G., Lane W.J., Soignet S.L., Warrell R.P. Jr., et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an anti-leukemic effect via inhibition of angiogenesis. Blood. 96:2000;1525-1530
38. Zhu J., Lallemand-Breitenbach V., de The H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene. 20(October(49)):2001;7257-7265
39. Dreyfus F., Bouscary D., Melle J., Ribrag V., Guesnu M., Varet B. Expression of EVI1 gene in myelodysplastic syndromes. Leukemia. 9:1995;203-205
40. Russell M., List A., Greenberg P., Woodward S., Glinsmann B., Parganas E., et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood. 84(August(4)):1994;1243-1248
41. Xi Z.F., Russell M., Woodward S., Thompson F., Wagner L., Taetle R. Expression of Zn finger gene, EVI1, in acute promyelocytic leukemia. Leukemia. 11(February(2)):1997;212-220